Leqembi Receives Positive Public Reimbursement Recommendation in Canada BioArctic announced that CDA-AMC has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for el...
Takeaways: The positive reimbursement recommendation from Canada’s drug agency moves Leqembi closer to public funding for early Alzheimer’s disease, which can significantly expand the ...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
